Allo BMT in Advanced Leukemia or High Grade Lymphoma

This study has been completed.
Sponsor:
Information provided by:
Stanford University
ClinicalTrials.gov Identifier:
NCT00186290
First received: September 13, 2005
Last updated: October 7, 2010
Last verified: October 2010
  Purpose

To evaluate the role of ablative allogeneic hematopoietic cell transplantation in the treatment of advanced leukemia or lymphoma.


Condition Intervention
Lymphoma, Non-Hodgkin
Leukemia
Blood and Marrow Transplant (BMT)
Lymphomas: Non-Hodgkin
Procedure: ablative allogeneic hematopoietic cell transplantation

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Fractionated Total Body Irradiation (FTBI), Etoposide (VP-16) and Cyclophosphamide (CY) Followed by Allogeneic Bone Marrow Transplantation for Patients With Advanced Leukemia or High Grade Lymphoma

Resource links provided by NLM:


Further study details as provided by Stanford University:

Primary Outcome Measures:
  • overall survival [ Time Frame: october 2009 ] [ Designated as safety issue: No ]
  • disease free survival [ Time Frame: October 2009 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • early and late toxicities of the treatment regimen [ Time Frame: October 2009 ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 145
Study Start Date: December 1989
Study Completion Date: October 2009
Primary Completion Date: October 2009 (Final data collection date for primary outcome measure)
Detailed Description:

To determine the disease free survival and overall survival of patients with ALL and ANLL after induction failure, in relapse, or subsequent remission from CML in several phases or recurrent lymphoblastic lymphoma who receive fractionated TBI, etoposide and cyclophosphamide followed by allogenic bone marrow grafting from histocompatible sibling donors. Fractionated Total Body Irradiation (FTBI), Etoposide (VP-16) and Cyclophosphamide (CY) Followed by Allogeneic Bone Marrow Transplantation for Patients with Advanced Leukemia or High Grade Lymphoma

  Eligibility

Ages Eligible for Study:   up to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:HLA identical donor

  • adequate organ function
  • other life threatening disease
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00186290

Locations
United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: Robert Lowsky Stanford University
  More Information

No publications provided

Responsible Party: Robert Lowsky, Stanford University School of Medicine
ClinicalTrials.gov Identifier: NCT00186290     History of Changes
Other Study ID Numbers: BMT34, 74165, BMT34
Study First Received: September 13, 2005
Last Updated: October 7, 2010
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Leukemia
Lymphoma
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases

ClinicalTrials.gov processed this record on April 17, 2014